Patents Assigned to MethylGene Inc.
  • Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors
    Patent number: 9193749
    Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: November 24, 2015
    Assignees: Forum Pharmaceuticals, Inc., MethylGene, Inc.
    Inventors: Robert Deziel, Silvana Leit, Patrick Beaulieu, Yves Andre Chantigny, John Mancuso, Pierre Tessier, Gideon Shapiro, Richard Chesworth, David Smil
  • Inhibitors of histone deacetylase
    Patent number: 9096565
    Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein groups L, M, X and Y are as defined herein.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: August 4, 2015
    Assignee: MethylGene Inc.
    Inventors: Pierre Tessier, Silvana Leit, David Smil, Robert Deziel, Alain Ajamian, Yves Andre Chantigny, Celia Dominguez
  • Processes and intermediates for preparing fused heterocyclic kinase inhibitors
    Patent number: 9018378
    Abstract: This invention relates to intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.
    Type: Grant
    Filed: July 19, 2013
    Date of Patent: April 28, 2015
    Assignee: Methylgene Inc.
    Inventors: Franck Raeppel, Ljubomir Isakovic, Stephen William Claridge, Michael Mannion, Lijie Zhan, Marie-Claude Granger, Arkadii Vaisburg
  • Processes and intermediates for preparing fused heterocyclic kinase inhibitors
    Patent number: 8907091
    Abstract: This invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.
    Type: Grant
    Filed: August 29, 2008
    Date of Patent: December 9, 2014
    Assignee: Methylgene Inc.
    Inventors: Franck Raeppel, Ljubomir Isakovic, Stephen William Claridge, Michael Mannion, Lijie Zhan, Marie-Claude Granger, Arkadii Vaisburg, Miguel Nantel
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8906852
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: December 9, 2014
    Assignee: MethylGene Inc.
    Inventors: Stéphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frédéric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8846927
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: September 30, 2014
    Assignee: MethylGene Inc.
    Inventors: Stephen William Claridge, Ljubomir Isakovic, Michael Mannion, Stephane Raeppel, Oscar Mario Saavedra, Frederic Gaudette, Lijie Zhan, Arkadii Vaisburg
  • Inhibitors of histone deacetylase and prodrugs thereof
    Patent number: 8796330
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: August 5, 2014
    Assignee: Methylgene Inc.
    Inventors: Robert Déziel, Alain Ajamian
  • METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY
    Publication number: 20140179632
    Abstract: This invention relates to methods for inhibiting kinase activity and/or inhibiting angiogenesis and/or treating a disease responsive to inhibition of kinase activity and/or treating a cell proliferative disease and/or treating an ophthalmic disease, condition or disorder treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions comprising administering novel compounds that inhibit protein tyrosine kinase activity.
    Type: Application
    Filed: February 28, 2014
    Publication date: June 26, 2014
    Applicant: MethylGene Inc.
    Inventors: Michael Mannion, Stephane Raeppel, Stephen William Claridge, Frederic Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8759522
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
    Type: Grant
    Filed: December 9, 2010
    Date of Patent: June 24, 2014
    Assignee: Methylgene Inc.
    Inventors: Michael Mannion, Stephane Raeppel, Stephen William Claridge, Frederic Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Histone deacetylase inhibitors for enhancing activity of antifungal agents
    Patent number: 8759400
    Abstract: The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, this invention relates to compositions and methods for selectively enhancing fungal sensitivity to antifungal compounds.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: June 24, 2014
    Assignee: MethylGene Inc.
    Inventors: Nafsika Georgopapadakou, Wenqi Hu, Nadia Campeol, Jean Bedard, Robert Deziel, Alain Ajamian
  • Inhibitors of protein tyrosine kinase activity
    Patent number: 8729268
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and opthalmological diseases, disorders and conditions.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: May 20, 2014
    Assignee: MethylGene Inc.
    Inventors: Michael Mannion, Stéphane Raeppel, Stephen William Claridge, Frédéric Gaudette, Lijie Zhan, Ljubomir Isakovic, Oscar Mario Saavedra, Tetsuyuki Uno, Masashi Kishida, Arkadii Vaisburg
  • Histone Deacetylase Inhibitors for Enhancing Activity of Antifungal Agents
    Publication number: 20140081017
    Abstract: The present invention relates to compositions and methods to selectively treat fungal infection. More particularly, the invention relates to compounds, compositions thereof, and methods for selectively enhancing fungal sensitivity to antifungal compounds.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 20, 2014
    Applicant: METHYLGENE INC.
    Inventor: METHYLGENE INC.
  • Inhibitors of histone deacetylase
    Patent number: 8673911
    Abstract: This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification.
    Type: Grant
    Filed: November 3, 2008
    Date of Patent: March 18, 2014
    Assignee: MethylGene Inc.
    Inventors: Tammy Mallais, Oscar Moradei, Alain Ajamian, Pierre Tessier, David Smil, Sylvie Frechette, Silvana Leit, Patrick Beaulieu, Robert Deziel, John Mancuso
  • INHIBITORS OF HISTONE DEACETYLASE
    Publication number: 20140045850
    Abstract: This invention relates to compounds and methods for the inhibition of HDAC enzymatic activity. More particularly, the invention provides for compounds of formula (I), (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein L, M, n, R, W, X and Y are as defined in the specification.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 13, 2014
    Applicant: METHYLGENE INC.
    Inventor: METHYLGENE INC.
  • INHIBITORS OF HISTONE DEACETYLASE AND PRODRUGS THEREOF
    Publication number: 20140024608
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds, prodrugs thereof, and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: March 14, 2013
    Publication date: January 23, 2014
    Applicant: METHYLGENE INC.
    Inventors: Robert Deziel, Alain Ajamian
  • Inhibitors of histone deacetylase
    Patent number: 8598168
    Abstract: The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Grant
    Filed: April 5, 2007
    Date of Patent: December 3, 2013
    Assignee: MethylGene Inc.
    Inventors: Oscar Moradei, Isabelle Paquin, Sylvie Frechette, Tammy Mallais, Simon Roy, Roger Machaalani, Arkadii Vaisburg, Jeffrey M Besterman, Pierre Tessier, David Smil, Silvana Leit, Robert Déziel
  • Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors
    Publication number: 20130310564
    Abstract: This invention relates to intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.
    Type: Application
    Filed: July 19, 2013
    Publication date: November 21, 2013
    Applicant: MethylGene Inc.
    Inventors: Franck Raeppel, Ljubomir Isakovic, Stephen William Claridge, Michael Mannion, Lijie Zhan, Marie-Claude Granger, Arkadii Vaisburg
  • Processes and intermediates for preparing fused heterocyclic kinase inhibitors
    Patent number: 8569503
    Abstract: This invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, particularly at an industrial level.
    Type: Grant
    Filed: December 20, 2011
    Date of Patent: October 29, 2013
    Assignee: MethylGene Inc.
    Inventor: Ljubomir Isakovic
  • INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY
    Publication number: 20130165477
    Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling and HGF receptor signaling. More particularly, the invention relates to compounds, compositions and methods for the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.
    Type: Application
    Filed: February 14, 2013
    Publication date: June 27, 2013
    Applicant: METHYLGENE INC.
    Inventor: MethylGene Inc.
  • Inhibitors of VEGF receptor and HGF receptor signalling
    Patent number: 8470850
    Abstract: The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling.
    Type: Grant
    Filed: May 6, 2010
    Date of Patent: June 25, 2013
    Assignee: MethylGene Inc.
    Inventors: Arkadii Vaisburg, Stephen William Claridge, Franck Raeppel, Oscar Mario Saavedra, Noemy Berstein, Marie-Claude Granger, Lijie Zhan, Amal Wahhab, David Liewellyn